Demcizumab: Completed Phase II enrollment

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab ( OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-...